01:46 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; skin cancer Mouse studies suggest combining anti-PD-L1 therapies and promoters of reactive oxygen species (ROS) production or agonists of the mTOR or AMPK signaling pathways could help treat colorectal and skin cancers. In...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

T cell gas, tumor brake

  A trio of studies has converged on a common pathway, headed by the PPAR co-activator PGC-1α, to fight cancer and chronic infections by manipulating either T cell immunotherapies or the tumors themselves. While the findings...
08:00 , Jan 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Peroxisome proliferation-activated receptor-a (PPARA; PPARa) Mouse studies suggest PPARa agonists could help...
07:00 , May 17, 2010 |  BC Week In Review  |  Clinical News

Tricor fenofibrate: Post-marketing study data

A meta-analysis of 45,058 patients in 18 placebo-controlled trials showed that fibrate therapy led to a 10% relative risk reduction of major cardiovascular events (p=0.048) and a 13% relative risk reduction for coronary events (p<0.0001)...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

CRx-401: Phase II data

Data from the double-blind, Canadian Phase II CRx-401-001 trial in 120 patients who are poorly controlled on metformin showed that CRx-401 plus metformin met the primary endpoint of significantly reducing fasting plasma glucose at day...
07:00 , Jun 1, 2009 |  BioCentury  |  Finance

Ebb & Flow

On its face, the deal to take out CuraGen Corp. (NASDAQ:CRGN) is returning about $0.18 for every dollar the genomics-based oncology company has raised since it went public. But the $94.5 million all-stock offer announced...
01:21 , May 28, 2009 |  BC Extra  |  Clinical News

CRx-401 meets diabetes endpoint

CombinatoRx Inc. (NASDAQ:CRXX) said CRx-401 plus metformin met the primary endpoint of significantly reducing fasting plasma glucose at day 90 compared to bezafibrate plus metformin in the Phase II CRx-401-001 trial to treat Type II...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Company News

CombinatoRx autoimmune, cancer, inflammation news

CombinatoRx restructured and reduced headcount across the company by about 50 (45%) to 90 to conserve cash. The company is seeking partners for its clinical compounds Synavive ( CRx-102), CRx-401, CRx-197 and CRx-191. Synavive,...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Clinical News

Hepaconda: Phase IIa halted

Giaconda said it voluntarily suspended an Australian Phase IIa trial of Hepaconda in non-responding patients with HCV genotype 1 infection because normalization was not achieved and further formulation work is warranted. The company said data...
08:00 , Feb 7, 2008 |  BC Innovations  |  Targets & Mechanisms

PPAR-alpha's in cancer

In a paper published in the Proceedings of the National Academy of Sciences, Harvard University researchers demonstrated an anticancer effect in mice taking oral doses of the generic dyslipidemia drug fenofibrate.1 The good safety profile...